BRCA2 and cancer: A pan-cancer analysis done on 33 cancers including cutaneous melanoma and uveal melanoma observed significantly higher HRDsum scores calculated based on LOH, LST, and TAI in patients with 22 different HRR mutations including BRCA1 and BRCA2.